Blood Cancer Drug Misses Key Trial Endpoint, Karyopharm Shares Drop 16%
summarizeSummary
Karyopharm Therapeutics announced disappointing late-stage clinical trial results for its myelofibrosis treatment, a combination of selinexor and ruxolitinib, which missed one of its primary endpoints. The study failed to demonstrate a statistically significant improvement in absolute total symptom score, leading to a 16% decline in the company's stock. While the trial did meet its other primary endpoint of spleen-volume reduction, analysts believe the missed endpoint significantly diminishes the likelihood of FDA approval, especially given regulators' focus on total symptom score superiority. This setback adds to the company's challenges, following a recent 'going concern' warning and previous clinical program setbacks, despite a recent $30 million private placement. Investors will now closely watch Karyopharm's upcoming discussions with the FDA regarding the data and its supplemental new drug application filing plan.
في وقت هذا الإعلان، كان KPTI يتداول عند ٥٫٥٧ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ١٠٢٫٢ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ٣٫٥١ US$ و١٠٫٩٩ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية سلبية وبدرجة أهمية ٩ من 10. المصدر: Dow Jones Newswires.